Publication avec DOI
Récupéré
Publication
crossref
Gonzalo Salazar de Pablo, Carolina Pastor Jordá, Julio Vaquerizo-Serrano, Carmen Moreno, Anna Cabras, Celso Arango, Patricia Hernández, Jeremy Veenstra-VanderWeele, et al.
(2023).
Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.
Journal of the American Academy of Child & Adolescent Psychiatry, 62(2), 151-168.
Elsevier BV.
- Date de publication
-
février 2023
- Identifiant
-
10.1016/j.jaac.2022.03.033
- Auteurs
-
Gonzalo Salazar de Pablo,
Carolina Pastor Jordá,
Julio Vaquerizo-Serrano,
Carmen Moreno,
Anna Cabras,
Celso Arango,
Patricia Hernández,
Jeremy Veenstra-VanderWeele,
Emily Simonoff,
Paolo Fusar-Poli,
Paramala Santosh,
Samuele Cortese,
Mara Parellada
- Source
- Journal of the American Academy of Child & Adolescent Psychiatry
- Détails
- 62(2), 151-168
- Type de référence
- article
- Éditeur
- Elsevier BV
- Source de métadonnées
- crossref
Résumé
OBJECTIVE: Emotional dysregulation and irritability are common in individuals with autism spectrum disorder (ASD). We conducted the first meta-analysis assessing the efficacy of a broad range of pharmacological interventions for emotional dysregulation and irritability in ASD and predictors of response. METHOD: Following a preregistered protocol (PROSPERO: CRD42021235779), we systematically searched multiple databases until January 1, 2021. We included placebo-controlled randomized controlled trials (RCTs) and evaluated the efficacy of pharmacological interventions and predictors of response for emotional dysregulation and irritability. We assessed heterogeneity using Q statistics and publication bias. We conducted subanalyses and meta-regressions to identify predictors of response. The primary effect size was the standardized mean difference. Quality of studies was assessed using the Cochrane Risk of Bias Tool (RoB2). RESULTS: A total of 2,856 individuals with ASD in 45 studies were included, among which 26.7% of RCTs had a high risk of bias. Compared to placebo, antipsychotics (standardized mean difference = 1.028, 95% CI = 0.824-1.232) and medications used to treat attention-deficit/hyperactivity disorder (ADHD) (0.471, 0.061-0.881) were significantly better than placebo in improving emotional dysregulation and irritability, whereas evidence of efficacy was not found for other drug classes (p >.05). Within individual medications, evidence of efficacy was found for aripiprazole (1.179, 0.838-1.520) and risperidone (1.074, 0.818-1.331). Increased rates of comorbid epilepsy (β = -0.049, p =.026) were associated with a lower efficacy. CONCLUSION: Some pharmacological interventions (particularly risperidone and aripiprazole) have proved efficacy for short-term treatment of emotional dysregulation and irritability in ASD and should be considered within a multimodal treatment plan, taking into account also the tolerability profile and families' preferences.
Auteur·ices de l’étude dans cette référence citée